Y.S.P. Industries


Y.S.P. Industries
Concise Prescribing Info
Ciprofloxacin HCl
Uncomplicated & complicated infections caused by ciprofloxacin-sensitive pathogens: Infections of the resp tract including pneumonia caused by Klebsiella, Enterobacter, Proteus, E coli, Pseudomonas, Haemophilus, Branhamella, Legionella, Staph; eye, kidneys &/or efferent urinary tract; genital organs including adnexitis, gonorrhoea, prostatitis; abdominal cavity, skin & soft tissue, bones & joint; otitis media, sinusitis; sepsis; patients whose immune system has been weakened; selective intestinal decontamination in immunosuppressed patients. Reduction of incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Dosage/Direction for Use
Adult Resp tract infection 2 x 250-500 mg tab for 7-14 days. Acute, uncomplicated UTI 2 x 125 mg tab to 1-2 x 250 mg tab up to 7 days; cystitis in women (premenopause) 250 mg single dose; complicated 2 x 250-500 mg tab up to 7 days. Extragenital gonorrhea 2 x 125 mg tab for 7-14 days; acute, uncomplicated gonorrhea 250 mg single dose. Diarrhea 1-2 x 500 mg tab for 7-14 days. Other infections 2 x 500 mg tab for 7-14 days. Strep pneumonia infection 2 x 750 mg tab for at least 10 days. Bone & joint infections 2 x 750 mg tab. Max duration: 2 mth in osteomyelitis. Peritonitis 2 x 750 mg up to 7 days. Recurrent infections in cystic fibrosis; septicemia; infections caused by Pseudomonas, Staph, Strep 2 x 750 mg for 7-14 days. Inhalational anthrax (post-exposure) Adult 500 mg bd. Childn 15 mg/kg bd. Max: 500 mg/dose. Do not exceed 1,000 mg daily dose. Total duration of treatment: 60 days.
May be taken with or without food: May be taken on an empty stomach for better absorption. Do not take w/ antacids, dairy products (eg, milk, yoghurt) or mineral-fortified drinks (eg, Ca-fortified orange juice). Swallow whole, do not chew.
Hypersensitivity to quinolones. Concomitant administration w/ tizanidine. Pregnancy & lactation. Childn <18 yr.
Special Precautions
Anaphylactic/anaphylactoid reactions. Increased transaminase, alkaline phosphatase or cholestatic jaundice. Epilepsy or previous CNS-disorders. Patients on corticosteroid therapy, kidney, heart & lung transplant recipients. Discontinue use if photosensitisation occurs. Avoid alcohol.
Adverse Reactions
Headache, dizziness, sleep & taste disorders, GI disorders eg, nausea, diarrhea, vomiting. GI & abdominal pain, dyspepsia, increased transaminase & bilirubin, rash, dyspnea.
Drug Interactions
Multivalent cation-containing drug & mineral supplement (eg, Ca, Mg, Al, Fe), polymeric phosphate binders (eg, sevelamar), sucralfate or anatacids, omeprazole, theophylline NSAIDs, cyclosporine, warfarin, glibenclamide, probenecid, methotrexate, metoclopramide, tizanidine, duloxetine, ropinirole, lidocaine, clozapine.
MIMS Class
ATC Classification
J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Ciflox FC tab 500 mg
10 × 10's;100 × 10's;3 × 10's;50 × 10's
Ciflox FC tab 750 mg
10 × 10's;100 × 10's;3 × 10's;50 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in